<article id="johnsen_2012" class="slide" data-ag-slide-name="Johnsen 2012">
    <div class="basic">
      <h1 data-ag-editable="Johnsen 2012 Main Title">G-CSF primary prophylaxis helps you to maintain the planned dose intensity for your patients on dose-dense regimens<sup>1</sup></h1>
      <div id="rdi_page3_data_top">
         <ul class="red_dot_list" data-ag-editable="Johnsen 2012 Top List Copy">
            <li class="red_subtitle2">16% of NHL patients given R-CHOP-14 did not receive G-CSF primary prophylaxis<sup>*1</sup></li>
         </ul>
      </div>
      <div id="rdi_page3_data_middle" class="rdi_page3_data_middle_class">
         <div id="rdi_page3_data_middle_left"><p data-ag-editable="Johnsen 2012 Left Graph Copy">Proportion of patients achieving RDI ≥90% when primary prophylaxis was given</p><div id="rdi_page3_data_graph1"><p data-ag-editable="Johnsen 2012 Left Graph Data">68%</p></div></div>
         <div id="rdi_page3_data_middle_right"><p data-ag-editable="Johnsen 2012 Right Graph Copy">Proportion of patients achieving RDI ≥90% when <u>no</u> primary prophylaxis was given</p><div id="rdi_page3_data_graph2"><p data-ag-editable="Johnsen 2012 Right Graph Data">47%</p></div></div>
      </div>
      <div id="rdi_page3_data_bottom">
         <ul class="red_dot_list" data-ag-editable="Johnsen 2012 Bottom List Copy">
            <li>RDI reduction is contrary to the intention of dose-dense regimens, and can result in inferior chemotherapy outcomes for your patients<sup>2</sup></li>
            <li>EORTC guidelines recommend primary prophylaxis G-CSF support to all patients receiving dose-dense regimens, where dose-dense or dose-intense chemotherapy strategies have survival benefit<sup>2</sup></li>
         </ul>
      </div>
    </div>
    <!-- Reference Information Starts -->
    <div class="lightbox_data" id="johnsen_2012_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="Johnsen 2012 References Title">References:</strong></p>
          <div data-ag-editable="Johnsen 2012 References List">
             <ol>
                <li>Johnsen HE <em>et al</em>. The importance of G-CSF prophylaxis in R-CHOP-14 therapy for diffuse large B-cell lymphoma in routine clinical practice. Leuk Lymphoma & Lymphoma, May 2012; 53(5):982-984</li>
                <li>Aapro M <em>et al</em>. 2010 update of EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47(1):8-32</li>
             </ol>
          </div>
          <p data-ag-editable="Johnsen 2012 References Bottom Copy">* Primary prophylaxis was defined as first course of G-CSF support initiated in days 1–7 of first chemotherapy cycle. Of 345 patients who received primary prophylaxis with G-CSF, 226 (66%) received Neulasta<sup>®</sup> and 119 (34%) received daily G-CSF</p>
       </div>
    </div>
    <!-- Reference Information Ends -->
</article>